Avalyn Pharma Inc. Common Stock (AVLN)
PHARMACEUTICAL PREPARATIONS
Avalyn Pharma Inc. Common Stock (AVLN) is listed on Nasdaq, where it has traded since April 30, 2026.
- Listed On
- Nasdaq
- Listed Since
- April 30, 2026
- Market Cap
- $1.2B
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 88 institutions reported holding AVLN, with 44.0 million shares worth $1.4 billion in aggregate. The largest reported holder was FMR, with 5.8 million shares worth $192.1 million. Of the 5 largest holders listed below, all 5 opened new positions in AVLN during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 5,835,259 | $192M | New position |
| Novo Holdings a/S | 3,883,289 | $128M | New position |
| T. Rowe Price | 3,337,976 | $110M | New position |
| SR One Capital Management | 3,308,649 | $109M | New position |
| Perceptive Advisors | 2,675,296 | $88M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is AVLN?
Avalyn Pharma Inc. Common Stock (AVLN) is listed on Nasdaq, where it has traded since April 30, 2026.
Who are the largest institutional holders of AVLN?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of AVLN were FMR, Novo Holdings a/S and T. Rowe Price.
How many institutions own AVLN?
88 institutions reported a position in AVLN for the quarter ended June 30, 2026, worth $1.4 billion in total.
Did institutions buy or sell AVLN last quarter?
Of the 5 largest reported holders, all 5 opened new positions in AVLN during the quarter. Every reported holder and its change is on the SentiSense ownership page for AVLN.
Every reported institutional holder, plus insider and congressional trades in AVLN, on SentiSense.